Indian drugmaker Sun Pharma has agreed to acquire US-based healthcare firm Organon in one of India's biggest outbound deals. Sun Pharma will pay $14 per Organon share in cash, giving it an enterprise valuation of $11.75 billion, according to a statement. Sun Pharma plans to fund the acquisition through a combination of available cash resources and committed financing from banks.